Identical and Non-Identical Twin Drugs

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 251-273

  Contreras, Jean Marie ^a   Bourguignon, Jean Jacques ^b  

^a Prestwick Chemical Inc   (France)

^b Laboratoire de Pharmacochimie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULES;

AMENTOFLAVONE; MOLECULAR VARIATION; NON-IDENTICAL; PHARMACOLOGICAL RESPONSE; POLYMER CHEMISTRY; POLYMERIC CHAIN; SINGLE MOLECULE; SPACER GROUPS;

POLYMERS;

EID: 84942892348     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50020-9     Document Type: Chapter

References (86)

1. Baldwin J.J., Lumma W.C., Lundell G.F., Ponticello G.S., Raab A.W., Engelhardt E.L., Hirschmann R., Sweet C.S., Scriabine A. Symbiotic approach to drug design: antihypertensive β-adrenergic blocking agents. J. Med. Chem. 1979, 22:1284-1290.
2. Cecchetti V., Fravolini A., Schiaffella F., Tabarrini O., Bruni G., Segre G. o-Chlorobenzenesulfonamidic derivatives of (aryloxy) propanolamines as β-blocking/diuretic agents. J. Med. Chem. 1993, 36:157-161.
3. Piwinski J.J., Wong J.K., Green M.J., Ganguly A.K., Billah M.M., West R.E., Kreutner W. Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta-[1,2-b]pyridin-11-ylene)piperidines. J. Med. Chem. 1991, 34:457-461.
4. Changeux J.P. Remarks on the symmetry and cooperative properties of biological membranes. Symmetry and Function of Biological Systems at the Macromolecular Level 1969, 235-256. Almqvist and Wiksell, New York. A. Engström, B. Strandberg (Eds.).
5. Blundell T., Sewell T., Turnell B. Symmetry in the structure and organization of proteins. Struct. Stud. Mol. Biol. Interest. 1981, 390-403. Oxford University Press, Stockholm. G. Dodson, J.P. Glusker, D. Sayre (Eds.).
6. Siddle K. The insulin receptor. Receptor Subunits and Complexes 1992, 261-351. Cambridge University Press, London. A. Burgen, E.A. Barnard (Eds.).
7. Ariëns E.J. Drug design - a general introduction. Drug Design 1971, 1-270. Academic Press, Cambridge. E.J. Ariëns (Ed.).
8. Bell M.R., Batzold F.H., Winneker R.C. Chemical control of fertility. Annual Reports in Medicinal Chemistry 1986, 169-177. Academic Press, New York. D.M. Bailey (Ed.).
9. Neupert-Laves K., Dobber M. The crystal structure of a K + complex of valinomycin. Helv. Chim. Acta 1975, 58:432-442.
10. Melchiorre C. Tetramine disulfides: a new tool in α-adrenergic pharmacology. Tr. Pharmacol. Sci. 1981, 2:209-211.
11. Kierstead R.W., Faraone A., Mennona F., Mullin J., Guthrie R.W., Crowley H. Beta-1-selective adrenoceptor antagonists. Blocking activity of a series of binary (aryloxy) propanolamines. J. Med. Chem. 1983, 26:1561-1569.
12. 2 muscarinic receptor antagonists. J. Med. Chem. 1993, 36:3734-3737.
13. Rosini M., Budriesi R., Bixel M.G., Bolognesi M.L., Chiarini A., Hucho F., Krogsgaard-Larsen P., Mellor I.R., Minarini A., Tumiatti V., Usherwood P.N.R., Melchiorre C. Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. J. Med. Chem. 1999, 42:5212-5223.
14. Rosini M., Bixel M.G., Marucci G., Budriesi R., Krauss M., Bolognesi M.L., Minarini A., Tumiatti V., Hucho F., Melchiorre C. Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. J. Med. Chem. 2002, 45:1860-1878.
15. Biftu T., Chabala J.C., Acton J., Beattle T., Brooker D., Bugianesi R. Synthesis and structure-activity relationship of 2, 5-diaryltetrahydrofurans as PAF antagonists. Prostaglandins 1988, 35:846.
16. Lamouri A., Heymans F., Tavet F., Dive G., Batt J.P., Blavet N., Braquet P., Godfroid J.-P. Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines. J. Med. Chem. 1993, 36:990-1000.
17. Roth R.A., Cassell D.J., Morgan D.O., Tatnell M.A., Jones R.H., Schüttler A., Brandenburg D. Effects of covalently linked insulin dimers on receptor kinase activity and receptor down regulation. FEBS Lett. 1984, 170:360-364.
18. 11-24 on steroidogenesis by synthesis of covalent dimeric conjugates. FEBS Lett. 1985, 183:283-286.
19. Chino N., Yoshizawa-Kumagaye K., Noda Y., Watanabe T.X., Kimura T., Sakakibara S. Synthesis and biological properties of antiparrallel and parallel dimers of human α-human atrial natriuretic peptide. Biochem. Biophys. Res. Comm. 1986, 141:665-672.
20. 2 receptor. J. Med. Chem. 1993, 36:2583-2584.
21. Costa T., Wuster M., Herz A., Shimohigashi Y., Chen H.-C., Rodbard D. Receptor binding and biological activity of bivalent enkephalins. Biochem. Pharmacol. 1985, 34:25-30.
22. Lin C.-E., Takemori A.E., Portoghese P.S. Synthesis and κ-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety required for κ-antagonist activity. J. Med. Chem. 1993, 36:2412-2415.
23. Portoghese P.S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10:230-235.
24. Joslyn A.F., Luchowski E., Triggle D.J. Dimeric 1,4-dihydropyridines as calcium channel antagonists. J. Med. Chem. 1988, 31:1489-1492.
25. Bridger G.J., Skerlj R.T., Padmanabhan S., Martellucci S.A., Henson G.W., Struyf S., Witvrouw M., Schols D., De Clerq E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. J. Med. Chem. 1999, 42:3971-3981.
26. De Clerq E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38:2491-2517.
27. Appelt K. Crystal structures of HIV-1 protease-inhibitor complexes. Persp. Drug Discov. Des. 1993, 1:23-48.
28. 2 symmetry. J. Am. Chem. Soc. 1991, 113:9382-9384.
29. Tan G.T., Wickramasinghe A., Verma S., Singh R., Hughes S.H., Pezzuto J.M., Baba M., Mohan P. Potential anti-AIDS naphtalenesulfonic acid derivatives. Synthesis and inhibition of HIV-1 induced cytopathogenesis and HIV-1 and HIV-2 reverse transcriptase activity. J. Med. Chem. 1992, 35:4846-4853.
30. 2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 249:527-533.
31. Hulten J., Bonham N.M., Nillroth U., Hansson T., Zuccarello G., Bouzide A., Aqvist J., Classon B., Danielson U.H., Karlen A., Kvarnstrom I., Samuelsson B., Hallberg A. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. J. Med. Chem. 1997, 40:885-897.
32. 2-symmetric HIV-1 protease inhibitors. Use of the l-mannaric acid as a peptidomimetic scaffold. J. Med. Chem. 1998, 41:3782-3792.
33. Davis P.D., Hill C.H., Lawton G., Nixon J.S., Wilkinson S.E., Hurst S.A., Keech E., Turner S.E. Inhibitors of protein kinase C. 1. 2.3-bisarylmaleimides. J. Med. Chem. 1992, 35:177-184.
34. Davis P.D., Elliott L., Harris W., Hill C.H., Hurst S.A., Keech E., Kumar H., Lawton G., Nixon J.S., Wilkinson S.E. Inhibitors of protein kinase C. 2. Substituted bisindolylymaleimides with improved potency and selectivity. J. Med. Chem. 1992, 35:994-1001.
35. Bit R.A., Davis P.D., Elliott L., Harris W., Hill C.H., Keech E., Kumar H., Lawton G., Maw A., Nixon J.S., Vesey D.R., Wadsworth J., Wilkinson S.E. Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J. Med. Chem. 1993, 36:21-29.
36. Trinks U., Buchdunger E., Furet P., Kump W., Mett H., Meyer T., Müller M., Regenass U., Rihs G., Lydon N., Traxler P. Dianilinophthalimides: Potent and selective. ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1994, 37:1015-1027.
37. Qin D., Sullivan R., Berkowitz W.F., Bittman R., Rotenberg S.A. Inhibition of protein kinase Cα by dequalinium analogues: Dependence on the linker length and geometry. J. Med. Chem. 2000, 43:1413-1417.
38. Thakkar K., Geahlen R.L., Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J. Med. Chem. 1993, 36:2950-2955.
39. Levitzki A., Gilon C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. 1991, 12:171-174.
40. Hales N.J., Beattie J.F. Novel inhibitors of prolyl 4-hydroxylase, 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives. J. Med. Chem. 1993, 36:3853-3858.
41. Ito N., Yasunaga T., Iizumi Y., Araki T Bis(ureidoalkyl)benzenes for inhibition of acylcoenzyme A cholesterol transferase (ACAT). European Patent Application EP 325 397. Chem. Abstr. 1990, 112:55271a. (26 July 1989, to Yamanouchi Pharmaceutical Co., Ltd).
42. Mao S.-S. Factor Xa inhibitors. Persp. Drug Discov. Des. 1993, 1:423-430.
43. Phillips G., Davey D.D., Eagen K.A., Koovakkat S.K., Liang A., Ng H.P., Pinkerton M., Trinh L., Whitlow M., Beatty A.M., Morrissey M.M. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J. Med. Chem. 1999, 42:1749-1756.
44. 1-acetyltransferase (SSAT) and as potential antitumor agents. J. Med. Chem. 1993, 36:2998-3004.
45. Stanek J., Caravatti G., Capraro H.-G., Furet P., Mett H., Schneider P., Regenass U. S-adenosylmethionine decarboxylase inhibitors: New aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone). J. Med. Chem. 1993, 36:46-54.
46. Taylor P., Lappi S. Interaction of fluorescence probes with acetylcholinesterase. The site and specificity of propidium binding. Biochemistry 1975, 14:1989-1997.
47. Pang Y.-P., Quiram P., Jelacic T., Hong F., Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. J. Biol. Chem. 1996, 271:23646-23649.
48. Stefanska B., Dzieduszycka M., Martelli S., Tarasiuk J., Bontemps-Gracz M., Borowski E. 6-[(Aminoalkyl)amino]-substituted 7H-benzo[e]perimidin-7-ones as novel antineoplastic agents. Synthesis and biological evaluation. J. Med. Chem. 1993, 36:38-41.
49. Wunz T.P., Dorr R.T., Alberts D.S., Tunget C.L., Einspahr J., Milton S., Remers W. New antitumor agents containing the anthracene nucleus. J. Med. Chem. 1987, 30:1313-1321.
50. Fairley T.A., Tidwell R.R., Donkor I., Naiman N.A., Ohemeng K.A., Lombardy R.J., Bentley J.A., Cory M. Structure, DNA minor groove binding, and base pair specificity of alkyl- and aryl-linked bis(amidinobenzimidazoles) and bis(amidinoindoles). J. Med. Chem. 1993, 36:1746-1753.
51. Mann J., Baron A., Opoku-Boahen Y., Johansson E., Parkinson G., Kelland L.R., Neidle S. A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. J. Med. Chem. 2001, 44:138-144.
52. Spicer J.A., Gamage S.A., Rewcastle G.W., Finlay G.J., Bridewell D.J.A., Baguley B.C., Denny W.A. Bis(phenazine-1-carboxamide): Structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. J. Med. Chem. 2000, 43:1350-1358.
53. Fröstl W., Maître L. The families of cognition enhancers. Pharmacopsychiatry 1989, 22:54-100. (Suppl).
54. Vennerstrom J.L., Ellis W.Y., Ager A.L., Anderson S.L., Gerena L., Milhous W.K. Bisquinolines, 1. N.N-bis(7-chloroquinolin-4-yl) alkanediamines with potential against chloroquine-resistant malaria. J. Med. Chem. 1992, 35:2129-2134.
55. Girault S., Grellier P., Berecibar A., Maes L., Mouray E., Lemière P., Debreu M.-A., Davioud-Charvet E., Sergheraert C. Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): Influence of the linker. J. Med. Chem. 2000, 43:2646-2654.
56. Rall T.W. Hypnotics and sedatives; ethanol. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1990, 345-382. Pergamon Press, San Diego. 8th edn. A. Goodman-Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.).
57. Brittain R.T., Drew G.M., Levy G.P. The α- and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers. Br. J. Pharmacol. 1980, 69:282p-283p.
58. Nicolaus B.J.R. Symbiotic approach to drug design. Decision Making in Drug Research 1983, 173-186. Raven Press, New York. F. Gross (Ed.).
59. 2 receptors. J. Med. Chem. 1993, 36:1488-1495.
60. Buschauer A. Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J. Med. Chem. 1989, 32:1963-1970.
61. 2 receptor antagonism combined in one molecule. J. Med. Chem. 1993, 36:1613-1618.
62. Zhang J.C., Entzeroth M., Wienen W. Characterization of BIBS 39 and BIBS 222: two new non peptide angiotensine II receptor antagonists. Eur. J. Pharmacol. 1992, 218:35-41.
63. Jacobson K.A., Lipkowski A.W., Moody T.W., Padgett W., Pijl E., Kirk K.L., Daly J.W. Binary drugs: Conjugates of purines and a peptide that bind to both adenosine and substance P. J. Med. Chem. 1987, 30:1529-1532.
64. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43:527-550.
65. Brooks D.A., Etgen G.J., Rito C.J., Shuker A.J., Dominianni S.J., Warshawsky A.M., Ardecky R., Paterniti J.R., Typhonas J., Karanewsky D.S., Kauffman R.F., Broderick C.L., Oldham B.A., Montrose-Rafizadeh C., Winneroski L.L., Faul M.M., McCarthy J.R. Design and synthesis of 2-methyl-2-(4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy)propionic acids: A new class of dual PPARα/γ agonists. J. Med. Chem. 2001, 44:2061-2064.
66. Unangst P.C., Connor D.T., Cetenko W.A., Sorenson R.J., Kostlan C.R., Sircar J.C., Wright C.D., Schrier D.J., Dyer R.D. Synthesis and biological evaluation of 5-[(3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with anti-inflammatory activity. J. Med. Chem. 1994, 37:322-328.
67. 2 synthase and aromatase. J. Med. Chem. 2000, 43:1841-1851.
68. Flynn G.A., Beight D.W., Mehdi S., Koehl J.R., Giroux E.L., French J.F., Hake P.W., Dage R.C. Application of a conformationally restricted Phe-Leu dipeptide mimetic to the design of a combined inhibitor of angiotensia I-converting enzyme and neutral endopeptidase 24.11. J. Med. Chem. 1993, 36:2420-2423.
69. Poatikis R., Dollé V., Guillaumel J., Dechaux E., Note R., Nguyen C.H., Legraverend M., Bisagni E., Aubertin A.-M., Grierson D.S., Monneret C. Synthesis and Evaluation of 'AZT-HEPT', 'AZT-Pyridinone', and 'ddC-HEPT' conjugates as inhibitors of HIV reverse transcriptase. J. Med. Chem. 2000, 43:1927-1939.
70. Camps P., El Achab R., Gorbig D.M., Morral J., Munoz-Torrero D., Badia A., Banos J.E., Vivas N.M., Barril X., Orozco M., Luque F.J. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J. Med. Chem. 1999, 42:3227-3242.
71. Mary A., Renko D.Z., Guillou C., Thal C. Potent acetylcholinesterase inhibitors: Design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem. 1998, 6:1835-1850.
72. 2 receptor antagonists and synthetase inhibitors. J. Med. Chem. 1994, 37:26-39.
73. 2 receptor antagonists and synthase inhibitors. J. Med. Chem. 1999, 42:1235-1249.
74. 2 synthase inhibition. J. Med. Chem. 1993, 36:2964-2972.
75. Wermuth C.G., Schlewer G., Bourguignon J.-J., Maghioros G., Bouchet M.-J., Moire C., Kan J.-P., Worms P., Bizière K. 3-Aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities. J. Med. Chem. 1989, 32:528-537.
76. Worms P., Kan J.P., Steinberg R., Terranova J.-P., Pério A., Bizière K. Cholinomimetic properties of minaprine. Naunyn-Schmiedeberg's Arch. Pharmacol. 1989, 340:411-418.
77. Wermuth C.G. Aminopyridazines - An alternative route to potent muscarinic agonist with no cholinergic syndrome. Il Farmaco 1993, 48:253-274.
78. Wermuth C.G., Bourguignon J.J., Hoffmann R., Boigegrain R., Brodin R., Kan J.P., Soubrié P. SR 46559 A and related aminopyridazines are potent muscarinic agonists with no cholinergic syndrome. Bioorg. Med. Chem. Lett. 1992, 2:833-838.
79. Contreras J.-M., Parrot I., Sippl W., Rival Y.M., Wermuth C.G. Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors. J. Med. Chem. 2001, 44:2707-2718.
80. Contreras J.-M., Rival Y.M., Chayer S., Bourguignon J.-J., Wermuth C.G. Aminopyridazines as acetylcholinesterase inhibitors. J. Med. Chem. 1999, 42:730-741.
81. Albrecht H.A., Beskid G., Christenson J.G., Deitcher K.H., Georgopapadakou N.H., Keith D.D., Konzelmann F.M., Pruess D.L., Wei C.C. Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone. J. Med. Chem. 1994, 37:400-407.
82. 1A serotonin receptors and serotonin transporter, as a new class of antidepressants. J. Med. Chem. 2001, 44:418-428.
83. Matzen L., van Amsterdam C., Rautenberg W., Greiner H.E., Harting J., Seyfriend C.A., Bottcher H. 5-HT reuptake inhibitors with 5-HT1B/1D antagonistic activity: A new approach toward efficient antidepressants. J. Med. Chem. 2000, 43:1149-1157.
84. Carrupt P.-A., Testa B., Bechalany A., El Tayar N., Descas P., Perrissoud P. Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. QSAR: Rational Approaches to the Design of Bioactive Compounds 1991, 541-544. Elsevier Science, New York. C. Silipo, A. Vittoria (Eds.).
85. Chi D.Y., O'Neil J.P., Anderson C.J., Welch M.J., Katzenellenbogen J.A. Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J. Med. Chem. 1994, 37:928-937.
86. Portoghese P.S., Sultana M., Takemori A.E. Design of peptidomimetic δ opioid receptor antagonists using the message-adress concept. J. Med. Chem. 1989, 33:1714-1720.